Survival of immunoglobulins from different species through the gastrointestinal tract in healthy adult volunteers: implications for human therapy.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to A K Bogstedt.
Explore the source record for details and available documents.
During the last years considerable attention has been focused on the possibility of the development of an oral vaccine against Helicobacter pylori. However, Helicobacter infection is known to be life-long, despite a vigorous immune response, and the hypothesis that an increased local production of secretory IgA in the gastric mucosa, due to vaccination, should protect against the colonization of the bacterium may therefore be questioned. In this study, when comparing the seropositivity and titre against H. pylori in IgA-deficient patients and age-related normal blood donors, it appears that lack of secretory IgA does not seem to have any major influence on the prevalence of the infection, nor is it reflected in titres of specific IgG antibodies. These results many argue against a pivotal role for IgA in the defence against Helicobacter, and raise questions about current strategies for the development of an oral vaccine against H. pylori and may point to a need for alternative therapeutic strategies.
Passive immunity against a variety of respiratory and gastrointestinal pathogens has recently been increasingly used clinically, and oral administration of antibodies of both human and non-human origin has been tried both for prophylaxis and treatment of infections. Although the former type of therapy has been shown to be effective, data on the latter are still scarce. This commentary focuses on recent studies on successful oral therapeutic administration of bovine immunoglobulins.
The aim of this study was to investigate the influence of large doses of orally administered human IgG on the normal gastrointestinal microflora of healthy volunteers since human immunoglobulin has been tried as oral prophylaxis and therapy in gastrointestinal infections. Ten adult healthy volunteers received 10 g of IgG orally, once daily for three consecutive days. Aerobic and anaerobic microorganisms were identified in the saliva and stool specimens, using morphological, biochemical and serological tests and gas-liquid chromatography. Although the immunoglobulin preparation contains antibodies against a variety of microorganisms, there were no significant changes in the numbers of different aerobic and anaerobic microorganisms due to the oral intake of the immunoglobulin. IgG may, therefore, be used against pathogens without disturbing the normal oral and intestinal microflora.